ArticleProstate international2025
The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel.
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KELIM PSA as a Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated with ARPI.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the prognostic value of the elimination rate constant K (KELIM), a marker of chemosensitivity, in mCRPC patients treated with docetaxel. Materials and methods: The study included patients who had received first-line docetaxel for mCRPC. The KELIM score was calculated using PSA measurements obtained within the first 100 days of chemotherapy. The patients were divided into two groups based on the KELIM levels: KELIM PSA <1 and KELIM PSA ≥1. The relationship between overall survival (OS) and the KELIM groups was evaluated. Results: A total of 164 patients were included in this study. The median age was 68.1 years (interquartile range (IQR) 62.2-71.1). There were 76 and 88 patients in the KELIM PSA <1 and KELIM PSA ≥1 groups, respectively. The median OS in the KELIM PSA ≥1 group (46.2 months, 95% confidence interval (CI): 38.8-53.6) was found to be longer than in the KELIM PSA <1 group (32.0 months, 95% CI: 23.1-40.9) ( Conclusions: Higher KELIM scores are positively correlated with improved overall survival in mCRPC patients treated with docetaxel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.